Fmoc-L-leucine
Inhibitors/Agonists
Fmoc-L-leucine is a derivative of the amino acid leucine, which is commonly used in peptide synthesis. It is a protected form of leucine, where the Fmoc (9-fluorenylmethoxycarbonyl) group is attached to the amino group of the leucine residue. This paper will discuss the method of synthesis or extraction of Fmoc-L-leucine, its chemical structure and biological activity, biological effects, applications in medical, environmental, and industrial research, and future perspectives and challenges.
353.4 g/mol
353.4 g/mol
Formulation:
353.4 g/mol
Source:
Usage:
Fmoc-L-leucine
The product is for non-human research only. Not for therapeutic or veterinary use.
Catalog Number: BT-250686
CAS Number: 35661-60-0
Molecular Formula: C21H23NO4
Molecular Weight: 353.4 g/mol
Purity: ≥ 98%
Inventory: In Stock
| Size | SKU | Price | |
|---|---|---|---|
| 5g | bt-250686-5g | $311.08 | |
| 10g | bt-250686-10g | $487.23 | |
| 25g | bt-250686-25g | $725.85 | |
| 100g | bt-250686-100g | $2,799.69 | |
| 500g | bt-250686-500g | $13,998.46 | |
| 1kg | bt-250686-1kg | $23,610.62 |
| CAS Number | 35661-60-0 |
|---|---|
| Product Name | Fmoc-L-leucine |
| Molecular Formula | C21H23NO4 |
| Molecular Weight | 353.4 g/mol |
| InChI | InChI=1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)/t19-/m0/s1 |
| InChI Key | CBPJQFCAFFNICX-IBGZPJMESA-N |
| Isomeric SMILES | CC(C)C[C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 |
| IUPAC Name | (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid |
| Canonical SMILES | CC(C)CC(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 |
| Description | Fmoc-L-leucine is a derivative of the amino acid leucine, which is commonly used in peptide synthesis. It is a protected form of leucine, where the Fmoc (9-fluorenylmethoxycarbonyl) group is attached to the amino group of the leucine residue. This paper will discuss the method of synthesis or extraction of Fmoc-L-leucine, its chemical structure and biological activity, biological effects, applications in medical, environmental, and industrial research, and future perspectives and challenges. |
| Method of Synthesis or Extraction | Fmoc-L-leucine can be synthesized using various methods, including solid-phase peptide synthesis (SPPS), solution-phase peptide synthesis, and enzymatic synthesis. SPPS is the most commonly used method for synthesizing Fmoc-L-leucine. It involves the stepwise addition of amino acids to a growing peptide chain, which is attached to a solid support. The Fmoc group is used as a temporary protecting group for the amino group of the leucine residue during the synthesis. After the peptide chain is synthesized, the Fmoc group is removed using a base, such as piperidine, to reveal the free amino group of the leucine residue. The efficiency and yield of the synthesis method depend on various factors, such as the quality of the starting materials, the reaction conditions, and the purification method. SPPS is a highly efficient method for synthesizing peptides, including Fmoc-L-leucine, with high yields and purity. However, it requires specialized equipment and expertise, and the process can be time-consuming. Environmental and safety considerations are important in the synthesis of Fmoc-L-leucine. The use of hazardous chemicals, such as piperidine, requires proper handling and disposal to prevent environmental contamination and health hazards. The use of alternative, safer reagents and solvents is encouraged to minimize the environmental impact and ensure safety. |
| Chemical Structure and Biological Activity | Fmoc-L-leucine has a chemical structure similar to that of leucine, with the addition of the Fmoc group to the amino group of the leucine residue. The Fmoc group is a common protecting group used in peptide synthesis to prevent unwanted reactions with the amino group. The biological activity of Fmoc-L-leucine depends on its mechanism of action and biological targets. It is commonly used in peptide synthesis to introduce leucine residues into peptides, which can affect the peptide's bioactivity and potency. Fmoc-L-leucine can also act as a substrate for enzymes that cleave the Fmoc group, releasing the free amino group of the leucine residue. |
| Biological Effects | Fmoc-L-leucine can affect cell function and signal transduction by modulating the activity of peptides that contain leucine residues. It can also affect the stability and conformation of peptides, which can affect their biological activity. The potential therapeutic and toxic effects of Fmoc-L-leucine depend on the peptides it is incorporated into and their biological targets. Peptides containing leucine residues have been studied for their potential therapeutic effects, such as antimicrobial, anticancer, and anti-inflammatory activities. However, the toxicity of peptides and their derivatives, including Fmoc-L-leucine, should be carefully evaluated to ensure their safety for use in humans. |
| Applications | Fmoc-L-leucine has various applications in medical, environmental, and industrial research. In medical research, it is commonly used in peptide synthesis for drug development and clinical trials. Peptides containing leucine residues have been studied for their potential therapeutic effects, such as in the treatment of cancer, infectious diseases, and inflammation. In environmental research, Fmoc-L-leucine can be used to study the effects of peptides on ecosystems and their role in pollution management. Peptides containing leucine residues have been found in wastewater and can affect the microbial community and nutrient cycling in aquatic environments. In industrial research, Fmoc-L-leucine can be used in manufacturing processes to improve product quality and efficiency. It can also be used in the development of new materials, such as hydrogels and biomaterials, for various applications. |
| Future Perspectives and Challenges | The use and study of Fmoc-L-leucine face various limitations and challenges, such as the high cost of synthesis, the limited availability of starting materials, and the need for specialized equipment and expertise. Possible solutions and improvements include the development of more efficient and cost-effective synthesis methods, the use of alternative starting materials, and the optimization of purification methods. Future trends and prospects in the application of Fmoc-L-leucine in scientific research include the development of new peptides and materials with improved bioactivity and properties. The use of peptides and their derivatives, including Fmoc-L-leucine, in drug development and clinical trials is expected to increase, with the potential for new therapies for various diseases. The use of peptides in environmental research is also expected to increase, with the potential for new insights into the effects of peptides on ecosystems and their role in pollution management. |
| Other CAS Number | 35661-60-0 |
| Pictograms | Irritant |
| SMILES | CC(C)CC(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 |
| Synonyms | Fmoc-L-leucine;35661-60-0;Fmoc-Leu-OH;N-Fmoc-L-leucine;Fmoc-L-Leu-OH;N-(9-fluorenylmethoxycarbonyl)-L-leucine;N-alpha-Fmoc-L-leucine;N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine;MLS002695993;L-LEUCINE,FMOCPROTECTED;CBPJQFCAFFNICX-IBGZPJMESA-N;(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoicacid;MFCD00037133;SMR001562137;ST50307349;(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoicacid;Fmocleucine;(2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-methylpentanoicacid;N-Fmocleucine;(2S)-2-([(9H-FLUOREN-9-YLMETHOXY)CARBONYL]AMINO)-4-METHYLPENTANOICACID;9-FLUORENYLMETHOXYCARBONYL-L-LEUCINE;FMOC-LEU;N-FMOC-LEUCINE;PubChem10022;FMOC-NLEU-OH |
| Reference | Xiong et al. Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors. Nature Chemistry, doi: 10.1038/nchem.2577, published online 25 July 2016 |
| PubChem Compound | Fmoc-L-leucine |
| Last Modified | May 30 2023 |